Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1What issues matter most to people with multiple myeloma and how well are we measuring them? A systematic review of quality of life tools2012 · 99 citations
2. 2Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S07772015 · 57 citations
3. 3Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results2014 · 28 citations
4. 4Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer2010 · 504 citations
5. 5Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma2005 · 341 citations